---
search:
  boost: 3
---

# Hypoglycemia Treatments

This is a subcategory of Endocrine Agents.

## Decision Tree

- [Endocrine - Diabetes - Hypoglycemia Treatments - Glucagon Emerg Kit[Labeler 00548 & 63323]](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUM00xMjFFUVlHUElMN0w1QVZOWVgwWVZROSQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                        | Generic Name                                                          | Quantity | Time (Days) |
| :----------------------------------------------- | :-------------------------------------------------------------------- | :------: | :---------: |
| Baqsimi One Pack <sup>QL</sup>                   | Clucagon Nasal Powder (all strengths)                                 |    6     |     102     |
| Baqsimi Two Pack <sup>QL</sup>                   | Clucagon Nasal Powder (all strengths)                                 |    3     |     102     |
| Glucagen Hypokit <sup>QL</sup>                   | Glucagon HCI (rDNA) for Inj 1 MG (all strengths)                      |    2     |     34      |
| Glucagon Emerg Kit [Labeler 00002] <sup>QL</sup> |                                                                       |          |             |
| Gvoke <sup>QL</sup>                              | Glucagon Subcutaneous Soln Inj (all strengths & formulations)         |    2     |     34      |
| Zegalogue <sup>QL</sup>                          | Dasiglucagon HCI Soln Subcutaneous Inj (all strengths & formulations) |    2     |     34      |

### Non-Preferred

| Non-Preferred                                            | Generic Name | Quantity | Time (Days) |
| :------------------------------------------------------- | :----------- | :------: | :---------: |
| Glucagon Emerg Kit [Labeler 00548 & 63323] <sup>QL</sup> |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^two preferred^^ drugs **OR** the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization 

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**QL** - All glucagon products: 2 doses per 34 days 

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=53){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=20){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
